Purpose To estimate rates and risk factors for progression to geographic atrophy (GA) or
choroidal neovascularization (CNV) among eyes diagnosed with early or intermediate age …

Purpose: To determine the impact of topographic locations on the progression rate of
geographic atrophy (GA). Methods: We searched in five literature databases up to May 3 …

Introduction: There is no effective treatment for geographic atrophy (GA). To help design
future GA treatment trials, we conducted a meta-analysis for GA growth rate and its variability …

Objectives To investigate the impact of qualitatively graded and deep learning quantified
imaging biomarkers on growth of geographic atrophy (GA) secondary to age-related …

Purpose To investigate the underlying reason for the previously observed impact of baseline
lesion size, number, and circularity on geographic atrophy (GA) growth rate. Design …

Background/aims Best-corrected visual acuity (BCVA) is the most common primary endpoint
in treatment trials for choroideremia (CHM) but the long-term natural history of BCVA is …

Topic Systematic review and meta-analysis of the natural history of autosomal recessive
Stargardt disease (STGD1). Clinical Relevance Controversy exists regarding the …

Purpose To investigate the topographic distribution of geographic atrophy (GA) and to
identify an anatomic endpoint that correlates with visual acuity (VA) in eyes with GA. Design …

Topic Determining the natural history of unifocal versus multifocal geographic atrophy (GA)
secondary to nonexudative age-related macular degeneration. Clinical Relevance The …

Purpose: To reclassify fundus autofluorescence (FAF) patterns around geographic atrophy
(GA) based on GA progression rates. Methods: MEDLINE, EMBASE, Cochrane Library …